Investors

Mauna Kea Technologies
Stock Information

Mauna Kea Technologies
Stock Information

Stay up to date on all our investor news

0,1130€

Last updated
14/10/2026 - 18:17

&

+1,07%

Events and Presentations

Financial Results

Governance 

News

Mauna Kea Technologies Announces 2026 Half-Year Results 

Mauna Kea Technologies Announces 2026 Half-Year Results 

Mauna Kea Technologies Announces Publication of a Landmark Systematic Review and Meta-Analysis Reinforcing the Diagnostic Accuracy and Clinical Impact of Cellvizio in Upper Gastrointestinal Cancer 

Mauna Kea Technologies Announces Publication of a Landmark Systematic Review and Meta-Analysis Reinforcing the Diagnostic Accuracy and Clinical Impact of Cellvizio in Upper Gastrointestinal Cancer 

Mauna Kea Technologies Announces Two New Peer-Reviewed Clinical Studies Confirming the Clinical Value of Cellvizio® and Its Combination with AI for the Diagnosis of Pancreatic Cysts 

Mauna Kea Technologies Announces Two New Peer-Reviewed Clinical Studies Confirming the Clinical Value of Cellvizio® and Its Combination with AI for the Diagnosis of Pancreatic Cysts 

No results found.

Shareholding Structure

Stock Information

IDENTIFICATION CODES

ISIN : FR0010609263

Ticker : ALMKT

ANALYST COVERAGE

ALLINVEST SECURITIES

Thibaut Voglimacci – Stephanopoli

EUROLAND CORPORATE
EUROLAND CORPORATE

Raphaël Génin

STATUTORY AUDITORS

• EY and Others, represented by Mr Franck SEBAG, 1-2 place des Saisons, 92400 Courbevoie- Paris La Défense, France

ANALYST REPORTS

View here